Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:1481
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2013  |  Volume : 27  |  Issue : 2  |  Page : 86-91

Long-term safety and efficacy of intralesional injection of triamcinolone acetonide for sternal keloid pain and pruritis: A double-blind comparison of two concentrations


1 Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Pharmacy Practice, Clinical Research Unit, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
3 Department of Cardiothoracic and Vascular Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Babita Ghai
Department of Anaesthesia, PGIMER, Sector 12, Chandigarh- 160 012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-5333.119342

Rights and Permissions

Background: Intralesional injection of triamcinolone acetonide (TAC) is the most frequently used treatment modality for keloids or hypertrophic scars. However, 20 mg/mL, triamcinolone is reported to have 50% incidence of adverse sequelae. We compared the long-term safety and efficacy of 10 mg/mL with 20 mg/mL intralesional injection of TAC on sternal keloid pain. Methods: Thirty adult patients presenting with pain and/or pruritis at sternal keloid site were randomized into one of the two groups. In group T20 patient received 1 mL of 20 mg/mL TAC, whereas in group T10 patients received 1 mL of 10 mg/mL of TAC intralesional every 2 weeks for a total of 3-4 treatments. Visual analog scale (VAS) scores for pain and pruritis, keloid/scar height, and any adverse sequelae were recorded at 2 weeks interval till 2 months and then at 6, 12, and 15 months. Primary outcome of the study was the percentage of patient developing side effects. Secondary outcome measures were VAS score for pain and itching, keloid height, and recurrence rate of pain or itching. Results: There was a significant decrease in VAS score for pain, pruritis, and keloid height after drug administration in both groups. Side effects was observed in 6 (40%) patients in group T20 and 1 (6.7%) patients in group T10 (P = 0.04). Two patients (13.3%) in group T20 and one in group T10 (6.7%) did not have any improvement in their pain/pruritis scores. Recurrence rate was 13.3% (2 patients) in T20 group compared with 20% (3 patients) in group T10 at 15 months after initial response. Conclusion: Intralesional injection of TAC in concentration of 10 mg/mL is as efficacious as 20 mg/mL for sternal keloid pain but is associated with significantly less side effects.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3561    
    Printed72    
    Emailed0    
    PDF Downloaded270    
    Comments [Add]    

Recommend this journal